The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
In the eye of the COVID-19 cytokine storm
Open accessAbstract
volume 20 | mAY 2020 | 277 Profiling of the innate immune cell types present in the KPC OG and KPL OG mouse models indicated that cDCs were markedly reduced in number and function in pancreatic tumours compared with in lung tumours. In the later stages of disease, there was a 79 fold reduction of cDC1s in pancreatic tumours compared with in lung tumours, and cDC1s in pancreatic tumours showed reduced expression of co stimulatory molecules and decreased antigen presenting capacity. Notably, similar observations were made when comparing cDC density in human PDAC and lung adenocarcinomas tissues. Treatment of KPC OG mice with FLT3L (which expands DC populations) in the early stages of PDAC led to increased pancreatic infiltration of cDCs and reduced tumour lesions; this was associated with a decreased TH17 type response and an increase in TH1 cell and cytotoxic CD8+ T cell responses in the pancreas. FLT3L treatment alone or in combination with anti CD40 did not lead to regression of established pancreatic tumours; however, the authors found that a triple combination therapy of FLT3L, anti CD40 and radiotherapy led to regression of established tumours in most KPPC OG mice. These findings suggest that cDC number and function can determine whether adaptive immune responses to tumour neoantigens are protective or detrimental in PDAC. Importantly, targeting cDCs may be crucial for effective therapies for PDAC, a disease that has been notoriously difficult to treat. Yvonne Bordon
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yang, Y., Shen, C., Li, J., Yuan, J., Wei, J., Huang, F., Wang, F., Li, G., Li, Y., Xing, L., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.04.027 · Cited by 872
Cited by
COVID-19: immunopathogenesis and Immunotherapeutics
Yang, L., Liu, S., Liu, J., Zhang, Z., Wan, X., Huang, B., Chen, Y., & Zhang, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00243-2 · Cited by 912
Bhaskar, S., Sinha, A., Banach, M., Mittoo, S., Weissert, R., Kass, J. S., Rajagopal, S., Pai, A. R., & Kutty, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01648 · Cited by 511
Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection
Montefusco, L., Ben Nasr, M., D’Addio, F., Loretelli, C., Rossi, A., Pastore, I., Daniele, G., Abdelsalam, A., Maestroni, A., Dell’Acqua, M., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00407-6 · Cited by 423
Veiga, V. C., Prats, J. A. G. G., Farias, D. L. C., Rosa, R. G., Dourado, L. K., Zampieri, F. G., Machado, F. R., Lopes, R. D., Berwanger, O., Azevedo, L. C. P., et al. (2021) · BMJ · doi:10.1136/bmj.n84 · Cited by 388
Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality
Zohar, T., Loos, C., Fischinger, S., Atyeo, C., Wang, C., Slein, M. D., Burke, J., Yu, J., Feldman, J., Hauser, B. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.052 · Cited by 297
“…mortality (Richardson et al., 2020; Williamson et al., 2020), emerging data suggest that inflammatory markers and cellular activation track with severity of disease (Kuri-Cervantes et al., 2020; Vaninov, 2020), pointing to a generalized activation of the immune response with progressive infection.”
Metadata
- Authors
- Vaninov, N.
- Venue
- Nature Reviews Immunology
- Published
- 2020-04-06
- Volume
- 20
- Issue
- 5
- Pages
- 277-277
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W3014361071
- Cited by
- 315
- References
- 1
- FWCI
- 8.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In the eye of the COVID-19 cytokine storm. https://app.cochat.ai/papers/10.1038/s41577-020-0305-6
- The paper
- Vaninov, N. (2020). In the eye of the COVID-19 cytokine storm. Nature Reviews Immunology. https://doi.org/10.1038/s41577-020-0305-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.